Best practice considerations by The American Society of Transplant and Cellular Therapy: Infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies Guidelines

  


Authors: Shahid, Z.; Jain, T.; Dioverti, V.; Pennisi, M.; Mikkilineni, L.; Thiruvengadam, S. K.; Shah, N. N.; Dadwal, S.; Papanicolaou, G.; Hamadani, M.; Carpenter, P. A.; Alfaro, G. M.; Seo, S. K.; Hill, J. A.
Title: Best practice considerations by The American Society of Transplant and Cellular Therapy: Infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies
Abstract: Chimeric antigen receptor (CAR) T-cell therapy is rapidly advancing, offering promising treatments for patients with hematological malignancy. However, associated infectious complications remain a significant concern because of their contribution to patient morbidity and non-relapse mortality. Recent epidemiological insights shed light on risk factors for infections after CAR T-cell therapy. However, the available evidence is predominantly retrospective, highlighting a need for further prospective studies. Institutions are challenged with managing infections after CAR T-cell therapy but variations in the approaches taken underscore the importance of standardizing infection prevention and management protocols across different healthcare settings. Therefore, the Infectious Diseases Special Interest Group of the American Society of Transplantation and Cellular Therapy assembled an expert panel to develop best practice considerations. The aim was to guide healthcare professionals in optimizing infection prevention and management for CAR T-cell therapy recipients and advocates for early consultation of Infectious Diseases during treatment planning phases given the complexities involved. By synthesizing current evidence and expert opinion these best practice considerations provide the basis for understanding infection risk after CAR T-cell therapies and propose risk-mitigating strategies in children, adolescents, and adults. Continued research and collaboration will be essential to refining and effectively implementing these recommendations. © 2024 The American Society for Transplantation and Cellular Therapy
Keywords: antibiotic agent; prospective study; antifungal agent; hematologic malignancy; chimeric antigen receptor; consultation; infection prevention; immunocompromised host; immunoglobulin deficiency; antibiotic prophylaxis; infection risk; infectious complication; infections; hematological malignancy; human; article; best practice; chimeric antigen receptor t-cell immunotherapy; car t-cell toxicities
Journal Title: Transplantation and Cellular Therapy
Volume: 30
Issue: 10
ISSN: 2666-6375
Publisher: Elsevier Inc.  
Date Published: 2024-10-01
Start Page: 955
End Page: 969
Language: English
DOI: 10.1016/j.jtct.2024.07.018
PUBMED: 39084261
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85202504336&doi=10.1016%2fj.jtct.2024.07.018&partnerID=40&md5=0a4e1a3c2edd7fb5efbe6489fb125867
Notes: Article -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Susan Seo
    121 Seo
  2. Genovefa A Papanicolaou
    238 Papanicolaou
  3. Zainab Shahid
    19 Shahid
Related MSK Work